Assessing Healthpeak Properties (DOC) Valuation After Recent Share Price Momentum

Healthpeak Properties (DOC) has drawn investor interest after recent share performance, with the stock up about 11% over the past month and around 13% in the past 3 months, alongside mixed annual revenue and net income trends.

See our latest analysis for Healthpeak Properties.

At a share price of $19.30, Healthpeak Properties has a 30 day share price return of 11.11% and a year to date share price return of 19.14%, while the 1 year total shareholder return is 17.67%. This hints that recent momentum has improved compared with the longer term, where the 5 year total shareholder return is down 24.81%.

If Healthpeak’s recent move has you thinking about where else to put capital to work in real assets and infrastructure, it can be useful to widen your search to 35 power grid technology and infrastructure stocks

With Healthpeak Properties’ shares recovering and trading around $19.30, the question now is whether the current valuation still leaves room for upside or if the recent run means the market is already pricing in future growth.

Most Popular Narrative: 4.3% Undervalued

Compared with the last close at $19.30, the most followed narrative pegs Healthpeak Properties’ fair value at about $20.17, implying a modest discount that investors may want to understand in more detail.

Ongoing, multi-year demographic tailwinds from an aging U.S. population are increasing demand for senior housing and independent living facilities (like Healthpeak's CCRC portfolio). This is supporting higher occupancy and growing entrance fees, which directly contribute to revenue and operating earnings growth.

Read the complete narrative.

Want to see what is baked into that fair value? The narrative leans on measured revenue expansion, firmer margins and a future earnings multiple far above sector norms. The exact mix of growth, profitability and valuation expectations is where the story gets interesting.

Result: Fair Value of $20.17 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors also need to weigh tenant credit risk in the lab segment and potential capital market disruption, either of which could pressure occupancy, funding, and earnings assumptions.

Find out about the key risks to this Healthpeak Properties narrative.

Another Angle: Multiples Paint a Tougher Picture

That 4.3% discount to the $20.17 fair value hinges on a narrative that is relatively supportive of Healthpeak. By contrast, the current P/E of about 60x sits well above both the estimated fair ratio of 28.7x and the Health Care REITs peer averages of 43.5x and 23.3x. For you, does that gap feel like opportunity or valuation risk?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Reading this, does Healthpeak look more promising or more pressured to you right now? Act quickly by reviewing both sides of the story with 1 key reward and 4 important warning signs

Looking for more investment ideas?

If Healthpeak has sharpened your focus on real assets, do not stop here. Broaden your watchlist with other angles that could suit your goals.

• Spot income potential by reviewing companies flagged as dividend fortresses through the 12 dividend fortresses.
• Hunt for quality at a sensible price by scanning stocks highlighted in the 54 high quality undervalued stocks.
• Prioritize resilience by focusing on companies identified in the 66 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com